Gravity Analytica

Opthea’s Wet AMD Program to be Featured at FLORetina 2024

OPT 11.26.2024

SERA-AI Powered Highlights

Drug:NCT04757636 sozinibercept

Diseases:wet age-related macular degeneration

Date of Upcoming Event:2024-12-05

Name of Upcoming Event:FLORetina Congress

Full Press Release SEC Filings Our OPT Tweets

About Gravity Analytica

Recent Filings

MELBOURNE, Australia, andPrinceton, N.J.,Nov. 26, 2024(GLOBE NEWSWIRE) --Opthea Limited(ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annualFLORetina Congressbeing held onDecember 5-8, 2024inFlorence, Italy. FLORetina aims to provide cutting-edge insights on research and clinical development from world-leading experts in the field of medical retina, retinal surgery, and imaging.

Details are as follows:

Session:	Retina Futura 1: Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates
Date:	Friday, December 6, 2024,11:25 AM CET
Presentation:	Beyond VEGF-A Inhibition: Will Blocking VEGF-C and VEGF-D Lead to Better Outcomes?
Presenter:	ProfessorAdnan Tufail, MBBS, MD, FRCOphth
Program:	https://floretina.com/floretinaicoormeeting2024/program

AboutOpthea

Opthea(ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST,NCT04757636, and ShORe,NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website atwww.opthea.comand follow us onXandLinkedIn.

Authorized for release to ASX byFrederic Guerard, PharmD, CEO

Investor InquiriesPJ KelleherLifeSci Advisors, LLCEmail:pkelleher@lifesciadvisors.comPhone: 617-430-7579

Media InquiriesSilvana Guerci-LenaNorthStream Global PartnersEmail:silvana@nsgpllc.com

Join our email database to receive program updates:Tel: +61 (0) 3 9826 0399, Email:info@opthea.comWeb:www.opthea.com

Source:Opthea Limited

Source: Opthea Limited

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com